<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705883</url>
  </required_header>
  <id_info>
    <org_study_id>Versión 4- 20/09/2020</org_study_id>
    <nct_id>NCT04705883</nct_id>
  </id_info>
  <brief_title>Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors</brief_title>
  <acronym>VIBRA</acronym>
  <official_title>Vaginal Prasterone In The Treatment Of Vaginal Atrophy In Patients With Breast Cancer Treatment With Aromatase Inhibitors (Vibra Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      VAGINAL PRASTERONE in the treatment of VAGINAL ATROPHY IN PATIENTS WITH BREAST CANCER&#xD;
      TREATMENT WITH AROMATASE INHIBITORS (VIBRA STUDY)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Verify a clinical improvement of AVV without increasing levels of ultrasensitive blood&#xD;
      estradiol in breast cancer survivors treated with aromatase inhibitors by administering&#xD;
      vaginal prasterone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 8, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estradiol</measure>
    <time_frame>12 months</time_frame>
    <description>Ultrasensitive blood estradiol, serum levels measured in pg/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal pH</measure>
    <time_frame>12 months</time_frame>
    <description>vaginal pH measured by ph roll from 1 to 14 (the lesser the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal maturation index</measure>
    <time_frame>12 months</time_frame>
    <description>vaginal maturation index meadured by vaginal citology on percentage from 0 to 100 divided in superficial, intermediate and basal cells. The more superficial, the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal health index</measure>
    <time_frame>12 months</time_frame>
    <description>To describe if there is a correlation between changes in the visual examination of the vagina. using the vaginal health index: from 5 to 25 (min-max). The higher the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index</measure>
    <time_frame>12 months</time_frame>
    <description>Questionaire from 18 to 90 (min-max). The higher the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Functioning Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Questionaire Social Functioning 12 (Physical and Mental Health Composite Scores) from 0 to 12 (min-max). The higher the better.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Vulvar Atrophy</condition>
  <condition>Breast Cancer</condition>
  <condition>Genitourinary Syndrome of Menopause</condition>
  <arm_group>
    <arm_group_label>Prasterone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 patients will be treated using prasterone during 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasterone (DHEA), Micronized</intervention_name>
    <description>Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.</description>
    <arm_group_label>Prasterone</arm_group_label>
    <other_name>Intrarosa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Breast cancer treated with anti-hormonal therapy based on inhibitors of aromatase (IA)&#xD;
             (letrozole, anastrozole or exemestane) ± analogues of the GnRH (aGnRH)&#xD;
&#xD;
          -  Menopause (natural or induced) and signs / symptoms of vulvovaginal atrophy&#xD;
&#xD;
          -  Cytology and / or determination of Human Papillomavirus (HPV) negative&#xD;
&#xD;
          -  Intention or willingness to have sex&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  To have received topical hormonal treatment in the last 6 months or Have used vaginal&#xD;
             moisturizers and / or lubricants during the 30 days prior to the study treatment&#xD;
&#xD;
          -  To have received treatment with laser, radiofrequency, hyaluronic acid, etc. in the&#xD;
             vagina during the last two years at the beginning of the study&#xD;
&#xD;
          -  To Have: an active infection of the genital tract; an intraepithelial neoplasm of the&#xD;
             cervix, vagina or vulva; suspected of suffering or having been treated for cancer of&#xD;
             the genital tract; suffer a genital prolapse of II degree or greater&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camil Castelo-Branco</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EDUARD M MENSION</last_name>
    <phone>626207171</phone>
    <email>edmension@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EDUARD M MENSION</last_name>
      <phone>626207171</phone>
      <email>edmension@gmail.com</email>
    </contact>
    <investigator>
      <last_name>EDUARD MENSION</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CAMIL CASTELO-BRANCO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Camil Castelo-Branco</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Genitourinary Syndrome of Menopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

